Revestive subcutaneous injection 3.8 mg, manufactured by Takeda Pharmaceutical, contains Teduglutide (genetical recombination). This medicine is an analog of glucagon-like peptide-2 (GLP-2) used to treat short bowel syndrome. It is provided as a 3.8mg 1 bottle (with dissolving solution) with YJ code 2499419D1026.
Revestive subcutaneous injection 3.8 mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).